MRI-guided microwave ablation of hepatic malignancies: 4-year institutional outcomes
PLOS One · 2026
DOI: 10.1371/journal.pone.0322917 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2026. Verfasst von Daniel Markus Düx und 7 weiteren Autor:innen. Beteiligte Einrichtung: Diagnostic and Interventional Radiology, Hannover Medical School, Hannover, Germany. Hauptthemen laut MEDLINE: Liver Neoplasms, Microwaves, Magnetic Resonance Imaging, Carcinoma, Hepatocellular. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bundesministerium für Bildung und Forschung, German Research Foundation.
Abstract (Originalsprache)
Purpose
We assessed the safety and efficacy of magnetic resonance (MR)-guided microwave ablation for treating hepatic malignancies.
Methods
This retrospective single-center review evaluated patients who underwent MR-guided microwave ablation for hepatic malignancies between 02/15/2017–04/22/2020. Complications were classified following CIRSE guidelines. Local tumor progression (LTP), local tumor recurrence (LTR), non-target progression (NTP), progression-free survival (PFS) and time to progression (TTP) were assessed, with data presented as mean ± standard deviation.
Results
Sixteen patients (60.75 ± 14.4 years; 9 males, 7 females) underwent 17 MR-guided microwave ablation for 21 hepatic malignancies (17 (81.0%) hepatocellular carcinoma, 1 (4.8%) cholangiocarcinoma, 2 (9.5%) metastases, and 1 (4.8%) suspicious lesion in a patient with primary sclerosing cholangitis). Lesion size was 12.2 ± 4.8 mm and total procedure time 138 ± 53 minutes. Complications included fever (N = 2), abdominal pain (N = 2), biloma (N = 1), and reactive cholecystitis (N = 1). These resolved with pain medication for one patient and antibiotics for another. No tumor recurrence was observed at ablation sites (LTP and LTR = 0%) at 36.7 ± 28.2 months. NTP occurred in 11 patients (68.8%) with a TTP of 14.8 ± 11.4 months. PFS was 44 months (95% CI: 10–85 months). Three patients died during follow-up — one from complications after liver transplantation and two from disease progression. Post-ablation liver transplantation was performed in two patients.
Conclusion
MR-guided microwave ablation for hepatic malignancies is safe and effective, with no local tumor recurrences noted over a follow-up period of 36.7 ± 28.2 months. Clinical significance MR-guided microwave ablation is a promising minimally invasive treatment for hepatic malignancies, demonstrating no LTR at 36.7 ± 28.2 months. Precise, radiation-free needle placement in real-time and effective targeting of small tumors may further improve future patient care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Diagnostic and Interventional Radiology, Hannover Medical School, Hannover, Germany.
- STIMULATE-Solution Centre for Image Guided Local Therapies, Magdeburg, Germany.
- Division of Interventional Radiology, Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, Connecticut, United States of America.
ORCID-Profile: Daniel Markus Düx, Frank Wacker, Bennet Hensen, Lena Becker
Förderung
- Bundesministerium für Bildung und Forschung
- German Research Foundation
Zitieren
APA
Düx, D. M., Gutberlet, M., Glandorf, J., Schröer, S., Ringe, K. I., Wacker, F., Hensen, B., & Becker, L. (2026). MRI-guided microwave ablation of hepatic malignancies: 4-year institutional outcomes. PLOS One. https://doi.org/10.1371/journal.pone.0322917
Vancouver
Düx DM, Gutberlet M, Glandorf J, Schröer S, Ringe KI, Wacker F, et al. MRI-guided microwave ablation of hepatic malignancies: 4-year institutional outcomes. PLOS One. 2026. doi:10.1371/journal.pone.0322917
BibTeX
@article{Dx2026,
author = {Düx, Daniel Markus and Gutberlet, Marcel and Glandorf, Julian and Schröer, Simon and Ringe, Kristina Imeen and Wacker, Frank and Hensen, Bennet and Becker, Lena},
title = {MRI-guided microwave ablation of hepatic malignancies: 4-year institutional outcomes},
journal = {PLOS One},
year = {2026},
doi = {10.1371/journal.pone.0322917}
}
EUVIMED